Biotech · Private company
Senju USA, Inc.
Track this companyFree. Adds Senju USA, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- SUN-131 1.5% TDSPhase 3 · ChalazionClinicalTrials.gov · fetched Nov 12, 2026
- Artificial tearsPhase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- Ketotifen 4.0% PatchPhase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- Olopatadine 0.2%Phase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- SUM-191Phase 2 · Bacterial ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Safety and Efficacy of SUM-191 for Patients With Bacterial ConjunctivitisPHASE1_PHASE2 · RECRUITING · started Jun 25, 2026ClinicalTrials.gov NCT07565103 · fetched Nov 12, 2026
- Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a ChalazionPHASE3 · COMPLETED · started Jul 31, 2017ClinicalTrials.gov NCT03248440 · fetched Nov 12, 2026
- Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic ConjunctivitisPHASE2 · COMPLETED · started Feb 1, 2009ClinicalTrials.gov NCT00836485 · fetched Nov 12, 2026